LTC1673106I2 - ŽPV 45 L1 optimizuota ekspresija mielėse - Google Patents

ŽPV 45 L1 optimizuota ekspresija mielėse

Info

Publication number: LTC1673106I2
Authority: LT; Lithuania
Prior art keywords: hpv; yeast; optimized expression; optimized; expression
Prior art date: 2003-09-29

Application number

LTPA2015049C

Other languages

English (en)

Original Assignee

Merck Sharp & Dohme Corp.

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2003-09-29

Filing date

2015-12-08

Publication date

2017-05-10

2015-12-08 Application filed by Merck Sharp & Dohme Corp. filed Critical Merck Sharp & Dohme Corp.

2017-05-10 Publication of LTC1673106I2 publication Critical patent/LTC1673106I2/lt

Links

240000004808 Saccharomyces cerevisiae Species 0.000 title 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
- C07K14/01—DNA viruses
- C07K14/025—Papovaviridae, e.g. papillomavirus, polyomavirus, SV40, BK virus, JC virus
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5258—Virus-like particles
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/20011—Papillomaviridae
- C12N2710/20022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/20011—Papillomaviridae
- C12N2710/20023—Virus like particles [VLP]
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/20011—Papillomaviridae
- C12N2710/20034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Genetics & Genomics (AREA)
General Health & Medical Sciences (AREA)
Engineering & Computer Science (AREA)
Medicinal Chemistry (AREA)
Virology (AREA)
Bioinformatics & Cheminformatics (AREA)
Biochemistry (AREA)
Molecular Biology (AREA)
Wood Science & Technology (AREA)
Zoology (AREA)
Immunology (AREA)
Biophysics (AREA)
Biomedical Technology (AREA)
Biotechnology (AREA)
Pharmacology & Pharmacy (AREA)
Public Health (AREA)
Proteomics, Peptides & Aminoacids (AREA)
General Engineering & Computer Science (AREA)
Veterinary Medicine (AREA)
Animal Behavior & Ethology (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Gastroenterology & Hepatology (AREA)
Microbiology (AREA)
Communicable Diseases (AREA)
Oncology (AREA)
Reproductive Health (AREA)
Endocrinology (AREA)
Physics & Mathematics (AREA)
Plant Pathology (AREA)
Micro-Organisms Or Cultivation Processes Thereof (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Preparation Of Compounds By Using Micro-Organisms (AREA)
Peptides Or Proteins (AREA)

LTPA2015049C 2003-09-29 2015-12-08 ŽPV 45 L1 optimizuota ekspresija mielėse LTC1673106I2 (lt)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US50681203P	2003-09-29	2003-09-29
PCT/US2004/031326 WO2005032586A1 (en)	2003-09-29	2004-09-24	Optimized expression of hpv 45 l1 in yeast

Publications (1)

Publication Number	Publication Date
LTC1673106I2 true LTC1673106I2 (lt)	2017-05-10

Family

ID=34421558

Family Applications (2)

Application Number	Title	Priority Date	Filing Date
LTPA2015049C LTC1673106I2 (lt)	2003-09-29	2015-12-08	ŽPV 45 L1 optimizuota ekspresija mielėse
LTPA2015049D LTPA2015049I1 (lt)	2003-09-29	2015-12-08	Žpv 45 l1 optimizuota ekspresija mielėse

Family Applications After (1)

Application Number	Title	Priority Date	Filing Date
LTPA2015049D LTPA2015049I1 (lt)	2003-09-29	2015-12-08	Žpv 45 l1 optimizuota ekspresija mielėse

Country Status (33)

Country	Link
US (2)	US7250170B2 (lt)
EP (1)	EP1673106B1 (lt)
JP (4)	JP5451960B2 (lt)
KR (1)	KR101165278B1 (lt)
CN (1)	CN1859923B (lt)
AR (2)	AR045804A1 (lt)
AT (1)	ATE435029T1 (lt)
AU (1)	AU2004277934B2 (lt)
BE (1)	BE2015C072I2 (lt)
BR (1)	BRPI0414845B8 (lt)
CA (1)	CA2539168C (lt)
CY (2)	CY1110525T1 (lt)
DE (1)	DE602004021828D1 (lt)
DK (1)	DK1673106T3 (lt)
ES (1)	ES2327530T3 (lt)
FR (1)	FR15C0083I2 (lt)
HU (1)	HUS1500063I1 (lt)
IL (1)	IL174458A (lt)
IS (1)	IS2694B (lt)
LT (2)	LTC1673106I2 (lt)
LU (1)	LU92902I2 (lt)
MX (1)	MXPA06003457A (lt)
MY (1)	MY140664A (lt)
NL (1)	NL300776I1 (lt)
NO (2)	NO339932B1 (lt)
NZ (1)	NZ545834A (lt)
PL (1)	PL1673106T3 (lt)
PT (1)	PT1673106E (lt)
RU (1)	RU2360001C2 (lt)
SI (1)	SI1673106T1 (lt)
TW (1)	TWI350853B (lt)
WO (1)	WO2005032586A1 (lt)
ZA (1)	ZA200601961B (lt)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
GB0206360D0 (en)	2002-03-18	2002-05-01	Glaxosmithkline Biolog Sa	Viral antigens
US7858098B2 (en) *	2002-12-20	2010-12-28	Glaxosmithkline Biologicals, S.A.	Vaccine
MY139500A (en)	2003-11-12	2009-10-30	Merck Sharp & Dohme	Optimized expression of hpv 58 l1 in yeast
ATE466022T1 (de)	2004-03-24	2010-05-15	Merck Sharp & Dohme	Optimierte expression von hpv-52-l1 in hefe
US7758866B2 (en)	2004-06-16	2010-07-20	Glaxosmithkline Biologicals, S.A.	Vaccine against HPV16 and HPV18 and at least another HPV type selected from HPV 31, 45 or 52
AU2006236905B2 (en)	2005-04-15	2010-06-03	The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services	Methods and compositions for producing an enhanced immune response to a human papillomavirus immunogen
EP1877086A2 (en) *	2005-04-26	2008-01-16	GlaxoSmithKline Biologicals SA	Vaccine
US8101342B2 (en) *	2006-08-28	2012-01-24	Sungkyunkwan University Foundation For Corporate Collaboration	DNA vaccine for treating or preventing cervical cancer comprising a gene encoding HPV protein
EP2129394B1 (en) *	2007-03-09	2012-06-20	Merck Sharp & Dohme Corp.	Papillomavirus vaccine compositions
EP2223933B1 (en) *	2007-11-23	2016-01-27	Shanghai Zerun Biotechnology Co., Ltd.	Genes encoding major capsid protein l1 of human papilloma viruses
TR201802597T4 (tr)	2009-06-19	2018-03-21	Eyegene Inc	Servikal kanseri için aşı.
EP2576840B1 (en)	2010-05-25	2018-10-17	QIAGEN Gaithersburg, Inc.	Fast results hybrid capture assay and associated strategically-truncated probes
EP2722389B1 (en)	2011-06-15	2018-03-07	Hong Jin Kim	Method for enhancing the production yield of human papillomavirus l1 protein
RU2610174C2 (ru)	2011-06-24	2017-02-08	Мерк Шарп И Доум Корп.	Вакцинные составы против вируса папилломы человека (hpv), содержащие алюминиевый адъювант, и способы их получения
CN109321592A (zh) *	2012-01-21	2019-02-12	北京安百胜生物科技有限公司	用汉逊酵母表达***产生hpv18 l1蛋白的方法
CN103361280B (zh) *	2012-03-28	2018-07-24	北京安百胜生物科技有限公司	用汉逊酵母表达***产生hpv11 l1蛋白的方法
CN104120088B (zh) *	2013-04-26	2019-09-24	北京安百胜生物科技有限公司	用汉逊酵母表达***产生hpv58 l1蛋白的方法
CN110484554B (zh) *	2013-04-26	2024-04-16	北京安百胜生物科技有限公司	用汉逊酵母表达***产生hpv52 l1蛋白的方法
CN104164447B (zh) *	2013-05-17	2019-08-13	北京安百胜生物科技有限公司	用汉逊酵母表达***产生hpv45 l1蛋白的方法
CN112280793B (zh) *	2013-09-29	2022-06-24	上海泽润生物科技有限公司	人***瘤病毒基因，及载体，菌株，表达方法
EP3057612B1 (en)	2013-10-16	2020-05-06	Merck Sharp & Dohme Corp.	Method of obtaining thermostable dried vaccine formulations
AU2015313756A1 (en) *	2014-09-11	2017-03-09	Cadila Healthcare Limited	Superior human papilloma virus antigens with superior immunological properties and vaccine containing it
CN106282278B (zh) *	2015-06-29	2021-06-08	广东东阳光药业有限公司	一种人***瘤病毒l1蛋白的发酵方法
CN106701798B (zh) *	2015-08-12	2021-09-17	北京康乐卫士生物技术股份有限公司	45型重组人***瘤病毒病毒样颗粒及其制备方法
CN109750050B (zh) *	2017-11-07	2023-08-18	上海泽润生物科技有限公司	重组人***瘤病毒45亚型蛋白表达
BR112022015313A2 (pt)	2020-02-14	2022-09-27	Merck Sharp & Dohme Llc	Vacina de hpv
CN112680462B (zh) *	2020-12-29	2022-02-22	上海博唯生物科技有限公司	一种人***瘤病毒35型/hpv35型l1/l2及其制备与应用
CN113073105B (zh) *	2021-03-23	2023-06-13	重庆博唯佰泰生物制药有限公司	一种表达hpv 56l1的多核苷酸序列及其表达载体、宿主细胞和应用
TW202313658A (zh)	2021-08-06	2023-04-01	美商默沙東有限責任公司	Hpv疫苗
TW202315602A (zh)	2021-08-19	2023-04-16	美商默沙東有限責任公司	新穎熱穩定脂質奈米粒子及其使用方法

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
PL183781B1 (pl) *	1994-05-16	2002-07-31	Merck & Co Inc	Sposób wytwarzania szczepionki przeciwko ludzkiemu wirusowi brodawczaków
AR004464A1 (es)	1994-11-14	1998-12-16	Merck Sharp & Dohme	Un metodo para producir una proteina de capside de papilomavirus
IL117459A (en) *	1995-03-22	2005-11-20	Merck & Co Inc	Dna encoding human papillomavirus type 18
IL117591A0 (en) *	1995-03-30	1996-07-23	Merck & Co Inc	Synthetic DNA encoding human papillomavirus type 11 L1 protein
DE69836206T2 (de)	1997-02-07	2007-08-23	Merck & Co., Inc.	Synthetische hiv gag gene
DE69732378D1 (de) *	1997-05-27	2005-03-03	Hanil Synthetic Fiber Co Ltd	Verfahren zur herstellung von rekombinanten eiweissen durch verwendung von hocheffizienten expressionsvektoren aus saccharomyces cerevisiae
EP1002091B1 (en)	1997-07-09	2012-02-29	Coridon Pty Limited	Nucleic acid sequence and method for selectively expressing a protein in a target cell or tissue
EP1105157B1 (en) *	1998-08-14	2006-11-02	Merck & Co., Inc.	Protein delivery system using human papillomavirus virus-like particles
US6991795B1 (en) *	1998-08-14	2006-01-31	Merck & Co., Inc.	Protein delivery system using human papillomavirus virus-like particles
CA2355883A1 (en) *	1998-12-23	2000-07-06	Merck & Co., Inc.	Neutralizing assay using human papillomavirus virus-like particles
DE60016765T2 (de) *	1999-08-25	2005-11-24	Merck & Co., Inc.	Synthetische papillomavirus gene, welche für expression in menschlichen zellen optimiert sind
US6436402B1 (en) *	1999-10-15	2002-08-20	Merck & Co., Inc.	Process for making human papillomavirus virus-like particles with improved properties
US7026443B1 (en) *	1999-12-10	2006-04-11	Epimmune Inc.	Inducing cellular immune responses to human Papillomavirus using peptide and nucleic acid compositions
BR0112637A (pt)	2000-07-21	2003-06-10	Glaxo Group Ltd	Sequências do vìrus do papiloma códon-otimizadas
AU2003219760A1 (en) *	2002-02-14	2003-09-04	Novavax, Inc.	Optimization of gene sequences of virus-like particles for expression in insect cells
GB0206360D0 (en)	2002-03-18	2002-05-01	Glaxosmithkline Biolog Sa	Viral antigens
EP1608767B1 (en)	2003-03-24	2012-02-22	Merck Sharp & Dohme Corp.	Optimized expression of hpv 31 l1 in yeast

2004
- 2004-09-21 MY MYPI20043867A patent/MY140664A/en unknown
- 2004-09-22 AR ARP040103420A patent/AR045804A1/es active IP Right Grant
- 2004-09-23 TW TW093128883A patent/TWI350853B/zh active
- 2004-09-24 DK DK04788982T patent/DK1673106T3/da active
- 2004-09-24 WO PCT/US2004/031326 patent/WO2005032586A1/en active Application Filing
- 2004-09-24 AT AT04788982T patent/ATE435029T1/de active
- 2004-09-24 PT PT04788982T patent/PT1673106E/pt unknown
- 2004-09-24 NZ NZ545834A patent/NZ545834A/en active IP Right Revival
- 2004-09-24 MX MXPA06003457A patent/MXPA06003457A/es active IP Right Grant
- 2004-09-24 CA CA2539168A patent/CA2539168C/en active Active
- 2004-09-24 BR BRPI0414845A patent/BRPI0414845B8/pt active IP Right Grant
- 2004-09-24 JP JP2006528190A patent/JP5451960B2/ja active Active
- 2004-09-24 PL PL04788982T patent/PL1673106T3/pl unknown
- 2004-09-24 RU RU2006114701/13A patent/RU2360001C2/ru active
- 2004-09-24 EP EP04788982A patent/EP1673106B1/en active Active
- 2004-09-24 DE DE602004021828T patent/DE602004021828D1/de active Active
- 2004-09-24 SI SI200431180T patent/SI1673106T1/sl unknown
- 2004-09-24 CN CN2004800281067A patent/CN1859923B/zh active Active
- 2004-09-24 ES ES04788982T patent/ES2327530T3/es active Active
- 2004-09-24 KR KR1020067006044A patent/KR101165278B1/ko active IP Right Grant
- 2004-09-24 AU AU2004277934A patent/AU2004277934B2/en active Active
- 2004-09-24 US US10/573,330 patent/US7250170B2/en active Active
2006
- 2006-03-08 ZA ZA200601961A patent/ZA200601961B/en unknown
- 2006-03-20 IS IS8362A patent/IS2694B/is unknown
- 2006-03-21 IL IL174458A patent/IL174458A/en active IP Right Grant
- 2006-04-28 NO NO20061876A patent/NO339932B1/no active Protection Beyond IP Right Term
2007
- 2007-05-23 US US11/805,453 patent/US7482015B2/en active Active
2009
- 2009-09-21 CY CY20091100973T patent/CY1110525T1/el unknown
2010
- 2010-07-07 AR ARP100102440A patent/AR077396A2/es not_active Application Discontinuation
2011
- 2011-03-02 JP JP2011045589A patent/JP2011152137A/ja active Pending
2014
- 2014-06-24 JP JP2014129350A patent/JP2014221052A/ja active Pending
2015
- 2015-11-30 NL NL300776C patent/NL300776I1/nl unknown
- 2015-12-02 HU HUS1500063C patent/HUS1500063I1/hu unknown
- 2015-12-04 FR FR15C0083C patent/FR15C0083I2/fr active Active
- 2015-12-07 CY CY2015050C patent/CY2015050I2/el unknown
- 2015-12-08 LU LU92902C patent/LU92902I2/xx unknown
- 2015-12-08 LT LTPA2015049C patent/LTC1673106I2/lt unknown
- 2015-12-08 LT LTPA2015049D patent/LTPA2015049I1/lt unknown
- 2015-12-09 BE BE2015C072C patent/BE2015C072I2/nl unknown
2016
- 2016-02-04 JP JP2016019712A patent/JP2016136947A/ja active Pending
2017
- 2017-04-05 NO NO2017012C patent/NO2017012I1/no unknown

Also Published As

Publication number	Publication date
PL1673106T3 (pl)	2009-12-31
BRPI0414845B1 (pt)	2020-10-13
ATE435029T1 (de)	2009-07-15
TW200521233A (en)	2005-07-01
NL300776I2 (lt)	2015-12-29
BRPI0414845B8 (pt)	2021-06-15
IL174458A0 (en)	2006-08-01
ES2327530T3 (es)	2009-10-30
AR077396A2 (es)	2011-08-24
EP1673106A1 (en)	2006-06-28
HUS1500063I1 (hu)	2016-02-29
JP2011152137A (ja)	2011-08-11
NO20061876L (no)	2006-04-28
FR15C0083I2 (fr)	2016-11-25
PT1673106E (pt)	2009-09-22
US7250170B2 (en)	2007-07-31
EP1673106B1 (en)	2009-07-01
CN1859923A (zh)	2006-11-08
NO2017012I1 (no)	2017-04-05
ZA200601961B (en)	2007-05-30
LTPA2015049I1 (lt)	2016-01-11
JP2016136947A (ja)	2016-08-04
WO2005032586A1 (en)	2005-04-14
CY2015050I1 (el)	2016-06-22
FR15C0083I1 (fr)	2016-08-01
AU2004277934B2 (en)	2009-09-17
JP2014221052A (ja)	2014-11-27
KR101165278B1 (ko)	2012-07-23
DK1673106T3 (da)	2009-11-09
NO339932B1 (no)	2017-02-20
DE602004021828D1 (de)	2009-08-13
CA2539168A1 (en)	2005-04-14
RU2360001C2 (ru)	2009-06-27
IS2694B (is)	2010-11-15
LU92902I2 (fr)	2016-03-08
US7482015B2 (en)	2009-01-27
NL300776I1 (lt)	2015-12-29
AR045804A1 (es)	2005-11-16
NZ545834A (en)	2009-02-28
JP5451960B2 (ja)	2014-03-26
BE2015C072I2 (lt)	2023-12-14
MXPA06003457A (es)	2006-06-05
MY140664A (en)	2010-01-15
SI1673106T1 (sl)	2009-12-31
US20060240040A1 (en)	2006-10-26
CN1859923B (zh)	2012-09-05
CY1110525T1 (el)	2015-04-29
US20080138361A1 (en)	2008-06-12
IS8362A (is)	2006-03-20
IL174458A (en)	2014-06-30
BRPI0414845A (pt)	2006-11-21
KR20070029628A (ko)	2007-03-14
CA2539168C (en)	2011-05-31
RU2006114701A (ru)	2007-11-10
JP2007507207A (ja)	2007-03-29
CY2015050I2 (el)	2016-06-22
AU2004277934A1 (en)	2005-04-14
TWI350853B (en)	2011-10-21

Publication	Publication Date	Title
LTC1673106I2 (lt)	2017-05-10	ŽPV 45 L1 optimizuota ekspresija mielėse
CY2015051I2 (el)	2016-06-22	Βελτιστοποιημενη εκφραση hpv 58 l1 σε ζυμομυκητα
LTC1730175I2 (lt)	2017-05-10	Optimizuota HPV 52 L1 raiška mielėse
DE60317699D1 (de)	2008-01-03	Fermentationsverfahren und -zusammensetzungen
DE502004008445D1 (de)	2008-12-24	Energieautarker sensor
DK1499197T3 (da)	2008-05-13	Törgærsammensætning
SE0102342L (sv)	2001-12-30	Modified yeast
ITMO20040195A1 (it)	2004-10-26	'kit per la raccolta e la collezione di figurine'.
ITFI20030193A1 (it)	2005-01-18	Lievito per vinificazione.